pronounced blockade of monocyte influx and another mutant (E143K) showed total loss of function. We believe that 35K-Fc will be a useful tool for exploring the role of CC chemokines in chronic inflammatory pathologies, and w e have i dentified a higher potency form of the molecule which may have potential therapeutic applications in chronic inflammatory disease.
INTRODUCTION
Fc fusion proteins and monoclonal antibodies that b lock the activity of circul ating inflammatory mediators are now an essential arm of therapies directed against chronic inflammatory pathologies such as rhe umatoid arthritis (Taylor and Feldmann, 2009) . One of the most successful drugs in this cla ss is the TNFR:Fc fusion protein etanercept (Enbrel), a fusion of TNFR2 with a human IgG1 Fc domain which functions as a decoy receptor for soluble TNFα (Moreland et al., 1997) . The addition of an Fc domain greatly increases the half life of the TNFR protein in plasma, such that dosing is reduced to once or twice weekly injections (Moreland et al., 1996) . A wide range of other soluble mediators could be targeted with this app roach, since n ot all pat ients respond to anti-TNF therapy and the efficacy of treatment may decrease over time, meaning novel targets are required (Taylor and Feldmann, 2009) . One candidate class of soluble inflammatory mediators is the chemokines or chemotactic cytokines, the low molecular weight proteins responsible for the co-ordinated migration of leu kocytes in response to inflammation and infection (Charo and R ansohoff, 2006; Mackay, 2001 ).
Most viruses e xpress a repertoire of proteins, including chemokine binding proteins, which interfere with the host immune response as a mean s to a void rapid elimination from the organism (Alcami, 2003) . Chemokines are divided into four families on the basis of structure; C, CC, CXC and CX 3 C (Zlotnik and Yoshie, 2000) , and viral chemokine binding proteins show differential specificity and may bind one family or multiple families. The M3 protein from murine gammaherpesvirus 68, for ex ample, binds and ina ctivates all known chemokines (Parry et al., 2000) .
All poxviruses, including vaccinia virus, express a soluble 35 kDa chemokine-binding protein named '35K' or vCCI (Alcami et a l., 1998; S mith et al., 1997) . 35K has no sequence homology with known proteins and the elucidation of its crystal structure showed an unusual beta-sandwich topology not seen elsewhere (Carfi et al., 1999) . 35K binds all known human and mouse CC chemokines with high affinity (in the low nanomolar range) and this activity contributes directly to virulence (B urns et al., 2002; Reading et al., 2003) . 35K shows the This article has not been copyedited and formatted. The final version may differ from this version. 5 highest affinity for a number of chemokines responsible for monocyte/macrophage recruitment including MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4) and RANTES (CCL5), and indeed b inds these chemokines with a higher aff inity than th ey bind their cognate receptors (Burns et al., 2002) . A solution structure of 35K in complex with the chemokine MIP-1β (CCL4) demonstrated that 35K binds tightly across the face o f the c hemokine, obscuring regions essential for chemokine receptor binding (Zhang et al., 2006) . This study, and others which generated mutant CC chemokines, identified key residues involved in the 35K-chemokine interaction (Beck et al., 2001; Zhang et al., 2006) . The critical residues in MCP-1 required for high affinity binding to 35K were identified as Arg18, Tyr13, and Arg24 -the same residues required for inte raction with the M CP-1 receptor CCR2 (Beck et al ., 2001 ). Thus, 35K may bind to chemokines in solution or bound onto t he cell surface by glycosaminoglycans, thereby preventing the adhesion and directed migration of cells expressing the appropriate chemokine receptors.
35K has been shown to reduce eosinophil infiltration in a guinea pig skin model of allergic inflammation and decreased airway inflammation in a model of allergic asthma (Alcami et al., 1998; Dabbagh et al., 2000) . Both these models are dominated by eotaxin induced inflammatory cell recruitment, a ch emokine which has moderate to low affinity for 35 K compared to other CC chemokines. The highest affinity ligands for 35K are the inflammatory chemokines known to recruit monocytes in chronic inflammatory pathologies including rheumatoid arthritis and atherosclerosis (Burns et al., 2002) . Indeed, our laboratories have
shown that viral delivery of 35K suppresses both diet-induced and vein graft atherosclerosis in Apoe -/-mice (Ali et al., 2005; Bursill et al., 2004; Bursill et al., 2008) .
Viral delivery of 35K is not ideal for several reasons including the inflammatory response generated by the virus, the d ifficulty in administering a known dose and the short ter m duration of expression in the case of adenovirus (Nayak and Herzog, 2010 
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MATERIALS AND METHODS
Materials
All cell culture media and buffers w ere obtained from PAA systems (Yeovil, UK) unless otherwise specified. All laboratory chemicals were from S igma-Aldrich (Gillingham, UK) unless otherwise specified. PCR primers were from Eurofins MWG Biotech (London, UK), PCR reagents were from Qiagen (C rawley, UK). Chemokines were purchased from Peprotech (London, UK).
Cloning and mutagenesis of 35K-Fc
DNA encoding 35K from vaccinia virus (Lister str ain) including the endogenous signal peptide was amplified from a ve ctor containing the entire 35K gene u sing the fo llowing primers F-GCATGCTAGCATGAAACAATATATCGTC R-
GCCGGAATTCGACACACGCTTTGAGTTT encoding a 5' N heI site and a 3' E coRI site using the HotStar Taq P CR kit from Qiagen according to m anufacturer's instructions. 35K
was cloned in frame and upstream of a human IgG1 Fc domain using the pSecTag2(C) vector (Invitrogen, Paisley, UK). The Fc portion had been previously mutated to contain the substitutions L234A, L235E and G 237A to abrogate Fc receptor binding and P 331S to prevent complement activation. 35K-Fc was mutated using the S tratagene QuikChange mutagenesis kit (Agilent Technologies, Stockport, UK) according to m anufacturer's instructions, and mutants screened by sequencing in both directions. The primers used for mutagenesis are listed in Table 1 . The MR-Fc construct described here is a non-functional mutant of the cysteine-rich domain of the mannose receptor fused to the same mutated IgG1
Fc (Taylor et al., 2004) and was a kind gift from Dr Philip Taylor (Department of Infection, Immunity and Biochemistry, Cardiff University).
Production of 35K-Fc protein
This article has not been copyedited and formatted. The final version may differ from this version. Cramlington, UK). Bound protein was washed 2x with PBS/0.01% Tween-20 then eluted with 0.5 M sodium citrate pH3 followed by neutralisation with 1.5 M Tris-HCl pH10. Eluted protein was dialysed 2x overnight against 4L PBS, then re-concentrated using a centrifugal concentrator with a 30 kDa cut-off (Generon, Maidenhead, UK). Protein yield was assessed using a NanoDrop spectrophotometer at 280nm, protein integrity was assessed on an SDS-PAGE gel, and endotoxin testing was performed using the Pyrogene recombinant factor C assay (Lonza, Slough, UK).
Bio-gel elicitation of primary mouse macrophages
All animal studies were conducted with ethical approval from the Dunn School of Pathology Local Ethical Review Committee and i n accordance with the UK Home Office regulations (Guidance on the O peration of Animals, Scientific Procedures Act, 1986). C57Bl6/J or SV129 mice (Harlan, UK) were injected intra-peritoneally (i.p.) with 1 ml of 2% Bio-gel P-100 fine polyacrylamide beads (45-90 µ m; Bio-rad laboratories, Hemel Hempstead, UK) suspended in PBS and 4 days later, mice were sacrificed and the peritoneum lavaged with 10 ml ice-cold PBS / 2 m M EDTA (for chemotaxis and xCELLigence assays). Room temperature PBS / EDTA was used for lavage of cells for calcium flux assays.
Calcium flux
Cells (1 x 10 7 /ml) were loaded with Fura-PE3 AM calcium sensitive dye (Merck, Nottingham, UK) at a concentration of 1.5 µM in calcium flux buffer (HBSS / 5 mM HEPES / 0.5% w/v This article has not been copyedited and formatted. The final version may differ from this version. 9 BSA) for 45 mins at room temperature with gentle agitation. Cells were washed twice with calcium flux buffer then resuspended at a concentration of 3 x 10 7 cells/ml. Calcium flux was assessed using a Perkin Elmer LS55 spectrofluorimeter in a cuvette containing 100 µl of cells and 300 µl buffer. Agonists were added in a volume of 10 µl at a concentration of 40x.
When 35K-Fc was used, agonists were pre-incubated with 35K-Fc for 2 hours at room temperature prior to assay.
Chemotaxis
Chemotaxis was assessed using Neuroprobe ChemoTx 96 w ell plates (R eceptor Technologies, Leamington Spa, UK) as described previously (Cash et al., 2008) . Agonists were assessed by fluorescence microscopy and quantified using MetaMorph software. Data are expressed as migration index, i.e. fold change over the response to media alone.
DiscoveRx PathHunter eXpress beta arrestin assay
The assay was performed according to manufacturer's instructions (DiscoveRx Corp., 
Roche xCELLigence ECIS assay
Experiments were performed using a 96 w ell xCELLigence SP instrument (Roche Diagnostics, Burgess Hill, UK). Bio-gel elicited macrophages were plated at 200,000 cells/well in 96 w ell xCELLigence plates i n OptiMEM media (Invitrogen, Paisley UK) and allowed to adhere for 6 hours before the media was changed to remove non-adherent cells.
The following day agonists were pre-incubated +/-35K-Fc for 2 hours at room temperature and then added to the cells and data collected every 2 seconds. T he data were normalised to addition o f media alone and then the maximum cell index (i.e. peak height) was calculated. Experiments using CCR2 transfected CHO cells were performed with 25000 cells per well.
Zymosan Induced Peritonitis
Zymosan-induced peritonitis was performed as described previously (Cash et al., 2009 ).
Briefly, C57Bl6/J mice (Harlan, UK) were injected i.p. with 10 µg zymosan A (Sigma-Aldrich, Gillingham UK) diluted in 0.5 ml PBS or vehicle alone. Two hours later, mice w ere injected with 15 µg 35K-Fc in 0.5 ml PBS or v ehicle alone. After a further tw o hours, mice were sacrificed and the peritoneal cavity was lavaged with 5ml PBS / 2mM EDTA. Peritoneal cell counts were performed using a haemocytometer and trypan blue exclusion and peritoneal exudate cells were stained with antibodies against Ly6G (BD Biosciences, Oxford, UK) and 7/4 (AbD Serotec, Kidlington, UK) and analysed by flow cytometry to assess neutrophi l and inflammatory monocyte recruitment (see supplementary figure 1 for representative primary data). Cell-free peritoneal lavage fluid was stored at -80 °C for later ELISA analysis.
35K sandwich ELISA
Maxisorb ELISA plates (Nunc, Rochester NY) were coated overnight at room temperature with vCCI (35K) capture antibody (R&D systems) at 1 µg/ml in PBS. Plates were washed 5x with dH 2 O then non-specific binding was blocked with blocking buffer (PBS / 0.25% BSA / This article has not been copyedited and formatted. The final version may differ from this version. multiplied by the lavage volume (5 ml) to obtain total µg 35K-Fc per peritoneal cavity.
JE sandwich ELISA
Peritoneal lavage samples were assayed for JE (mouse CCL2/MCP-1) concentration using a Duoset sandwich ELISA (R&D systems, Abingdon, UK) according to manufacturer's instructions. Samples were assayed undiluted. Calculated concentrations were multiplied by the lavage volume (5 ml) to obtain total ng JE per peritoneal cavity.
This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
35K-Fc specifically blocks CC chemokine induced calcium flux and chemotaxis
Purified 35K-Fc protein w as tested for its ability to block CC chemokine signalling in a calcium flux assay with stably transfected 300.19 murine B cells. 300.19 CCR2 cells showed a robust calcium flux in response to the CC chemokine MCP-1 (CCL2), but failed to respond to the CX 3 C chemokine fractalkine (FK / CX 3 CL1; Figure 1A ). Similarly, 300.19 CX 3 CR1 cells responded to fractal kine, but showed no response to M CP-1 (Figure 1 B) . Both cell lines responded to SDF-1α (CXCL12) via their endogenous CXCR4 receptor ( Figure 1A and B).
MCP-1 pre-incubated w ith 35K-Fc failed to induce a c alcium flux in 300.19 CCR2, and a second addition of MCP-1 also failed to induce signalling -presumably due to rapid binding and inactivation of the chemokine by 35K-Fc ( Figure 1C ). SDF-1α still induced a calcium signal, indicating a specific blockade of CC chemokine signalling ( Figure 1C ). Furthermore, 35K-Fc had no effect on the response to the CX 3 C chemokine fractalkine in 300.19 CX 3 CR1 cells ( Figure 1D) . A second addition of fractalkine failed to induce a cal cium flux response, presumably due to homologous desensitisation of the CX 3 CR1 receptor ( Figure 1D ).
To further confirm the specificity of the CC chemokine blockade by 35K-Fc, we performed a calcium flux assay in primary Bio-gel elicited murine macrophages. These cells showed a robust calcium flux response to the CC chemokine agonist MIP-1α (CCL3) and the nonchemokine GPCR agonist leukotriene B4 (LTB4) which acts through the BLT1 receptor (data not shown). 35K-Fc almost completely abrogated the response to MIP-1α, but had no effect on the response to LTB4 ( This article has not been copyedited and formatted. The final version may differ from this version. 
13
We next tested whether 35K-Fc could inhibit chemotaxis of primary macrophages towards CC chemokines. Bio-gel elicited murine macrophages were allowed to migrate towards increasing concentrations of MIP-1α and showed a bell-shaped dose response curve, which is typical in this modified Boyden chamber assay ( Figure 2C ). We then chose a fixed dose of 0.5 nM MIP-1α, and pre-incubated the chemokine with increasing doses of 35K-Fc for 1 hour prior to addition to the as say. 35K-Fc induced a do se dependent blockade of M IP-1α-induced migration which was statistically significant at doses of 5, 10 and 20 nM ( Figure 2D ).
35K-Fc had no effect on macrophage chemotaxis towards the potent chemoattractant chemerin (a non-chemokine) at any dose tested (data not shown).
Site directed mutagenesis and screening by PathHunter eXpress beta-arrestin GPCR assay
Site directed mutagenesis of MCP-1, a high affinity ligand for 35K, indicated that the residues Y13, R18 and R24 in the chemokine were essential for binding to both 35K and the MCP-1 receptor, CCR2 (Beck et al., 2001 ). These residues are highly conserved among all CC chemokines, and a solution structure of MIP-1β bound to rabbitpox 35K indicated that these same residues were closely contacted by 35K and highlighted the critical residues involved (Zhang et al., 2006) . We targeted a number of residues within 35K based on the information provided by the co-structure. D141 and E143 interact closely with the positively charged R18 residue in the chemokine, w e therefore generated charge-swap mutants D141R, E143K and E143R and alanine m utants D141A and E143A, as w ell as a D141L mutant with a larger, hy drophobic, uncharged side chain. P he13 in th e chemokine was shown to contact a cluster of hydrophobic residues including V185 and Y217. We generated alanine mutants at these two residues, and also generated a polar Y217N mutant in order to disrupt the hydrophobic binding site. Finally, mutagenesis of MCP-1 by Beck et al. revealed that the mutation K49A in MCP-1 increased its affinity for 35K by 3 fold, possibly by relieving steric hindrance in th is region of int eraction (Beck et al., 2001 ). In the c o-structure, this residue was found to be closely contacted by the residues Y80 and R89 in 35K (Zhang et al.,
This article has not been copyedited and formatted. The final version may differ from this version. In order to screen the mutants for their effect on CC chemokine activity, we utilised a ra pid and robust GPCR signalling assay based on β -arrestin recruitment in transfected cell lines (DiscoveRx PathHunter eXpress).
RANTES induced a dose-dependent activation of CCR5 with an EC 50 of 2nM ( Figure 3A) . To test the effect of 35K-Fc on CCR5 activation by RANTES, 5nM RANTES (the EC 80 in this assay) was pre-incubated for 2 hours with 35K-Fc at a range of concentrations then added to the assay. WT 35K-Fc inhibited CCR5 activation and beta-arrestin recruitment with an IC 50 of 5.6 nM ( Figure 3B ). MR-Fc had no effect on CCR5 activation by RANTES at any dose tested ( Figure 3B ).
To screen the mutants, 5 nM RANTES was pre-incubated with 35K-Fc at a fixed dose (15 nM) for 2 hours then added to the assay. When RANTES was pre-incubated with WT 35K-Fc, the response was approximately 38% of that with RANTES alone ( Figure 3C ). All other Figure 3C ).
We hypothesised that the two mutants Y80A and R89A would show an increased ability to block chemokine signalling. In fact, the Y80A mutant showed complete loss of functi on indicating that this residue is e ssential for contact with K49 in the chemokine. In contrast,
R89A showed an enhanced blockade of RANTES signalling compared to W T 35K-Fc
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(p<0.001), reducing the response to 18% co mpared to R ANTES alone ( Figure 3C ). The control protein, M R-Fc was completely unable to bloc k RANTES signalling, showing the specificity of the CC chemokine blockade ( Figure 3C ). We also screened selected mutants in a second signalling assay (xCELLigence) using CCR2 transfected cells which measures the effect of chemokines on electric cell-substrate impedance sensing (see below). Data for all mutants is summarised in Table 2 .
R89A is a more potent inhibitor of in vitro chemokine activity than WT 35K-Fc
We chose to take two mutants for further analysis in vitro, the loss-of-function mutant E143K
and the R89A mutant with enhanced inhibitory activity. In a CCR2 beta-arrestin assay, WT 35K-Fc inhibited the response to MCP-1 with an IC 50 of 12.9 nM in the experiment shown, while R89A 35K-Fc was significantly more potent (p<0.001) and inhibited MCP-1 signalling with an I C 50 of 2.8 nM ( Figure 4B , pooled data from independent experiments is shown in Table 2 ). In a CCR5 beta-arrestin assay, WT 35K-Fc inhibited the response to RANTES with an IC 50 of 7.2 nM in the expe riment shown, while R89A 35K-Fc was again more potent (p<0.05) and inhibited RANTES signalling with an IC 50 of 2.5 nM ( Figure 4D , pooled data from independent ex periments is shown in Table 2 ). R 89A also s howed a m ore potent blockade of the CCR7 ligand MIP-3β (CCL19; p<0.01; Table 2 ). In contrast, E143K 35K-Fc had no effect on either MCP-1 or RANTES induced receptor activation, indicating it is a lossof-function mutant ( Figure 4B and D, Table 2 ). Neither WT nor R89A 35K-Fc were able to block the activity of IL-8 (CXCL8) on the CXCR2 receptor, indicating a specific blockade of CC chemokine activity only ( Figure 4F ).
To test w hether the mutants showed similar activity on primary cell responses to chemokines, we utilised an electric cell-substrate impedance sensing (ECIS) assay (Roche xCELLigence) which measures changes in cell impedance as a re sult of functional responses (Yu et al., 2005) . P rimary Bio-gel elicited primary murine macrophages were plated in a 96 well xCELLigence plate, where the base of the plate is covered with gold electrodes. Alternating current is passed through the cell monolayer every 2 seconds and This article has not been copyedited and formatted. The final version may differ from this version. figure 5A and 5B respectively. Figure 5E , pooled data from independent experiments is shown in Table   2 ). R89A 35K-Fc was approximately twice as potent as WT 35K-Fc (p<0.05), and inhibited the response with an IC 50 of 1.7 nM in the experiment shown ( Figure 5E , pooled data from independent experiments is shown in Table 2 ). E143K was completely unable to inhibit the response to MIP-1α ( Figure 5E ). To confirm that R89A 35K-Fc remained a specific inhibitor of CC chemokines, we used the CXC chemokine SDF-1α in the same assay. In primary murine macrophages, SDF-1α induced an increase in ce ll index with an E C 50 of approximately 4.7 nM ( Figure 5B and 5D ). Neither WT nor R89A 35K-Fc had any effect on the response when pre-incubated with SDF-1α prior to addition to the assay ( Figure 5F ).
R89A shows enhanced blockade of monocyte recruitment in vivo compared to WT
35K-Fc
In order to test the effect o f wild-type and mutant 35K-Fc on inflammatory cell recruitment in vivo, we utilised a sterile model of peritonitis induced by the y east cell wall component zymosan (Cash et al., 20 09) . To determi ne whether 35K-Fc could inhibit ongoing inflammation, mice were injected intraperitoneally with zymosan, then 2 hours l ater were injected with wild-type or mutant 35K-Fc. A low dose of 35K-Fc was chosen (15 µg) such that potential differences in activity between mutants could be quantified. Peritoneal lavage was carried out 2 hours later (after 4 hours overall) and total cell counts were performed as This article has not been copyedited and formatted. The final version may differ from this version. Figure 6A ; p<0.05) but had no effect on neutrophil influx ( Figure 6B ) or total cell numbers in the cavity (data not shown). The R89A mutant also significantly blocked monocyte recruitment into the ca vity by 43% (Figu re 6A; p<0.001),
while the E 143K mutant showed total loss of function and h ad no effect on monocyte recruitment ( Figure 6A ).
We also assessed the level of the CC chemokine JE (mouse MCP-1/CCL2) in peritoneal lavage fluid from the same animals using an ELISA capable of detecting free chemokine and In this study we found that although WT and R89A 35K-Fc were able to significantly reduce monocyte infiltration into the perit oneal cavity, the apparent level of the monocy te chemoattractant JE was increased. This is in line with previous studies from our laboratory which showed that adenoviral delivery of 35K increased the plasma level of the CC chemokines RANTES and MIP-1α while reducing the bioactivity of these chemokines (Bursill et al., 2003) . We interpret this finding as evidence that 35K-Fc is able to bind and sequester chemokines in solution, preventing both their activity and clearance. Thus, the higher potency R89A mutant showed the m ost striking inhibition of monocyte recruitment, but conversely induced the largest increase in detectable JE levels, while the E143K mutant neither reduced monocyte recruitment nor affected the peritonea l JE level compared to zymosan alone. This is consistent with two possible hypotheses. Firstly, since the binding sites for 35K and GAGs (glyocsaminoglycans) on chemokines are independent and differ in affinity by up to 1000 fold (35K having a low nM affinity, and GAGs an approximate µM affinity (Burns et al., 2002; Lau et al., 2004) ), 35K-Fc may 'strip' chemokines bound to GAGs on the cell surface, thus increasing their apparent concentration in solution while disrupting chemokine gradients known to be e ssential for migration in vivo (Proudfoot et al., 2003) .
Secondly, binding to 35K -Fc may prevent the normal routes of chemokine clearance and
This article has not been copyedited and formatted. The final version may differ from this version. (Boring et al., 1998; Braunersreuther et al ., 2007) . H owever, targeting a si ngle chemokine or chemokine receptor m ay not prove successful since the chemokine network shows a significant level of redundancy: most chemokines bind 'promiscuously' to more than one chemokine receptor and many key chemokine receptors have multiple high affinity chemokine ligands. Indeed a recent study targeting a singl e chemokine receptor (CCR2) in a therosclerosis with a small molecule antagonist could not halt plaque progression in experimental animals (Olzinski et al., 20 10) . In comparison, our laboratories have previously shown that both adenoviral and longer term lentiviral delivery of 35K is sufficient to reduce both macrophage content and plaque size in a mouse model of atherosclerosis (Bursill et al., 2004; Bursill et al., 2008) .
In this study we have generated a series of novel 35K-Fc fusion proteins which identify the key residues involved in CC chemokine blockade. Furthermore, we have generated a mutant This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. Column 2 summarises data shown in figure 3C and This article has not been copyedited and formatted. The final version may differ from this version. 
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TABLES
